Full history for every metric is available with a Kvantra account
Qilian International Holding Group Limited (QLI)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 50 | 46 | 50 | 57 | 65 | 46 | 46 |
| Operating profit | $m | -3 | -3 | |||||
| Net profit | $m | 5 | 5 | 5 | 3 | 1 | -8 | -8 |
| EPS reported | $ | -0.22 | -0.22 | |||||
| Operating cashflow per share | $ | 0.01 | 0.01 | |||||
| Capex per share | $ | 0.10 | 0.10 | |||||
| FCF per share | $ | -0.10 | -0.10 | |||||
| Free cash flow | $m | -3 | -3 | |||||
| Net debt | $m | -22 | -22 | |||||
| Book value equity | $m | 43 | 43 | |||||
| Book value per share | $ | 1.20 | 1.20 | |||||
| Number of shares | m | 35.75 | 35.75 | |||||
| DPS (TTM paid) | $ | 0.05 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 3.29 | 0.90 | |||||
| P/S LTM | x | 3.03 | 0.83 | |||||
| P/FCF LTM | x | -41.41 | -11.37 | |||||
| EV/EBITDA LTM | x | -105.09 | -11.46 | |||||
| EV/Sales LTM | x | 2.88 | 0.36 | |||||
| Earnings Yield LTM | % | -5.52% | -4.02% | |||||
| FCF Yield | % | -2.42% | -8.79% | |||||
| Quality | ||||||||
| ROE | % | -18.18% | -16.24% | |||||
| ROIC | % | -5.78% | -5.78% | |||||
| Operating margin | % | -5.62% | -5.62% | |||||
| Gross margin | % | 1.31% | 1.31% | |||||
| FCF/Sales | % | -7.32% | -7.32% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -28.35% | -28.35% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 1.27% | 0.00% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | -22.97% | -22.97% | |||||
| FCF/Debt | x | -5.89 | -5.89 | |||||
| Net Debt/EBITDA | x | 5.41 | 5.41 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -15.58% | -56.53% | |||||
| Net debt/Equity | x | -0.51 | -0.51 | |||||
| Gross debt/equity | x | 0.01 | 0.01 | |||||
Company overview
Qilian International Holding Group Limited (QLI), founded in 2019 and headquartered in Jiuquan, People's Republic of China, focuses on the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMDs), and a variety of other products. The company's diverse offerings include licorice-derived products such as Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, supplied to pharmaceutical companies for manufacturing traditional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient for producing compound licorice oral solutions. QLI also produces Qilian Shan oxytetracycline tablets, used to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and humans, alongside Qilian Shan oxytetracycline APIs for other pharmaceutical manufacturers. Its TCMD line features Ahan antibacterial paste, designed for addressing stubborn chronic skin ailments. Furthermore, the company provides heparin sodium preparations to pharmaceutical firms for developing medications related to cardiovascular diseases, cerebrovascular conditions, and hemodialysis. Beyond the medical sector, Qilian International offers Zhu Xiaochang natural sausage casings for culinary applications. In agriculture, it produces Xiongguan organic fertilizers, formulated to improve crop yield, enhance soil chemical properties, and reduce compaction, as well as Xiongguan organic-inorganic compound fertilizers to stimulate plant growth.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Qilian International Holding Group Limited (QLI)
Qilian International Holding Group Limited (QLI), founded in 2019 and headquartered in Jiuquan, People's Republic of China, focuses on the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMDs), and a variety of other products. The company's diverse offerings include licorice-derived products such as Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, supplied to pharmaceutical companies for manufacturing traditional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient for producing compound licorice oral solutions. QLI also produces Qilian Shan oxytetracycline tablets, used to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and humans, alongside Qilian Shan oxytetracycline APIs for other pharmaceutical manufacturers. Its TCMD line features Ahan antibacterial paste, designed for addressing stubborn chronic skin ailments. Furthermore, the company provides heparin sodium preparations to pharmaceutical firms for developing medications related to cardiovascular diseases, cerebrovascular conditions, and hemodialysis. Beyond the medical sector, Qilian International offers Zhu Xiaochang natural sausage casings for culinary applications. In agriculture, it produces Xiongguan organic fertilizers, formulated to improve crop yield, enhance soil chemical properties, and reduce compaction, as well as Xiongguan organic-inorganic compound fertilizers to stimulate plant growth.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free